Sun Pharma Advanced Research Company Ltd has appointed Anil Raghavan as Managing Director and Chief Executive Officer effective August 11, 2026, subject to shareholder approval. The Board of Directors approved the appointment during a meeting held on July 13, 2026. Raghavan, currently the Chief Executive Officer of the company, will assume the new role immediately following the retirement of the incumbent director.

Leadership Transition

Dr. Rajamannar Thennati will retire from the Board of Directors upon completion of his term as a Director at the ensuing 21st Annual General Meeting scheduled for August 10, 2026. The company stated that Raghavan is not related to any other director and is not debarred from holding the office of director by any SEBI order or other authority.

The following table summarises the key management changes:

Profile of the Incoming MD & CEO

Raghavan is responsible for developing and executing strategies to realize the company's vision of becoming a global pharmaceutical leader. He operates from the company's Mumbai office. Additionally, he serves as a mentor at AIRAMATRIX Private Limited, an early-stage Machine Learning company focusing on high content image processing and deep learning for drug development and clinical practice.

Prior to his current role, Raghavan spent a decade consulting with leading firms such as Arthur Andersen, KPMG, and Cambridge Technology Partners. He assisted leadership teams in various sectors, including Media and Entertainment, Telecommunications, and Health Care services, in developing business strategies and improving performance. He is an Industrial Engineer and an active speaker at industry events.

Regulatory Disclosures

The disclosures were made to the National Stock Exchange of India Ltd. and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kajal Damania, Company Secretary and Compliance Officer, signed the regulatory filing.

Sun Pharma Advanced Research Company Ltd sun pharma advanced research co will hold its 21st Annual General Meeting on Monday, August 10, 2026, at 04:30 P.M. IST via video conference. The meeting covers the financial year 2025-26, and shareholders must determine their eligibility by the cut-off date to participate and vote. The company has published a public notice regarding the meeting in the Financial Express on July 09, 2026, complying with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board has established Monday, August 03, 2026, as the "Cut-off Date" to determine shareholder eligibility for voting and attending the AGM. The Annual Report for FY 2025-26, which includes the Notice of the AGM, will be sent electronically to shareholders with registered email addresses and will be available on the company's website. Kajal Damania, Company Secretary and Compliance Officer, signed the intimation on July 09, 2026.

Key AGM Details

Shareholders are advised to verify and update their contact details, including email IDs and addresses, with their Depository Participants and the company's Registrar and Transfer Agent. This step is necessary to ensure the timely delivery of the Annual Report and facilitate participation in the e-voting process. The Notice of the AGM outlines specific procedures for registering or updating email and bank details, casting votes through e-voting, and attending the meeting via video conference.